

# RareÈ CÄlin CrÄciun

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5206728/publications.pdf>

Version: 2024-02-01

18  
papers

203  
citations

1040056

9  
h-index

1125743

13  
g-index

18  
all docs

18  
docs citations

18  
times ranked

246  
citing authors

#	ARTICLE	IF	CITATIONS
1	Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. <i>Clinical and Translational Oncology</i> , 2019, 21, 702-712.	2.4	38
2	SERS-Based Liquid Biopsy of Gastrointestinal Tumors Using a Portable Raman Device Operating in a Clinical Environment. <i>Journal of Clinical Medicine</i> , 2020, 9, 212.	2.4	23
3	Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 94, 107467.	3.8	18
4	Viscoelastic tests in liver disease: where do we stand now?. <i>World Journal of Gastroenterology</i> , 2021, 27, 3290-3302.	3.3	16
5	Nutritional Risk Assessment Scores Effectively Predict Mortality in Critically Ill Patients with Severe COVID-19. <i>Nutrients</i> , 2022, 14, 2105.	4.1	15
6	Endoscopic or percutaneous biliary drainage in hilar cholangiocarcinoma: When and how?. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2050-2063.	2.0	14
7	Percutaneous ultrasound guided radiofrequency and microwave ablation in the treatment of hepatic metastases. A monocentric initial experience.. <i>Medical Ultrasonography</i> , 2019, 21, 217.	0.8	13
8	Liver Injury and Elevated FIB-4 Define a High-Risk Group in Patients with COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 153.	2.4	13
9	Hepatic Hydrothorax – An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3688.	2.4	11
10	Recent advances in surface-enhanced Raman spectroscopy based liquid biopsy for colorectal cancer (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	1.8	10
11	Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward?. <i>Journal of Clinical Medicine</i> , 2021, 10, 903.	2.4	9
12	Contrast enhancement for ultrasound-guided interventions: when to use it and what to expect?. <i>Ultrasonography</i> , 2022, 41, 263-278.	2.3	6
13	Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1896-1918.	2.0	5
14	Malnutrition and non-compliance to nutritional recommendations in patients with cirrhosis are associated with a lower survival. <i>World Journal of Hepatology</i> , 2020, 12, 829-840.	2.0	3
15	Novel approaches in search for biomarkers of cholangiocarcinoma. <i>World Journal of Gastroenterology</i> , 2022, 28, 1508-1525.	3.3	3
16	Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1518-1528.	2.8	2
17	Association between PNPLA3[G]/I148M variant, steatosis and fibrosis stage in hepatitis C virus - genetic matters. <i>Journal of Physiology and Pharmacology</i> , 2019, 70, .	1.1	2
18	Pulmonary complications of portal hypertension: The overlooked decompensation. <i>World Journal of Clinical Cases</i> , 2022, 10, 5531-5540.	0.8	2